Two AI-driven disruptors, one biotech-focused, one software-first, post double-digit growth but diverge sharply on risk, cash flow, and valuation.

Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) is one of the 9 Stocks Crushing the Market With Surging Returns. Recursion Pharmaceuticals snapped two straight days of losses on Thursday, surging 9.51 ...

View Recursion Pharmaceuticals, Inc. Class A RXRX stock quote prices, financial information, real-time forecasts, and company news from CNN.

Recursion Pharmaceuticals (RXRX) is back in focus as investors weigh fresh updates on its AI-driven drug discovery platform, along with progress in key clinical assets REC-1245 and REC-4881 and ...

Detailed price information for Recursion Pharmaceuticals Inc Cl A (RXRX-Q) from The Globe and Mail including charting and trades.

This week, I had to make one of the most difficult decisions of my career: saying goodbye to 20% of the team at Recursion. The process was extraordinarily painful, and the costs were heartbreakingly ...

AI drug pioneer Recursion Pharmaceuticals said Wednesday that one of its experimental treatments hit a key milestone. Recursion was able to use its artificial intelligence-enabled drug discovery ...

Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced that on May 26, 2026, the Compensation Committee of Recursion's Board of ...

It has been about a month since the last earnings report for Recursion Pharmaceuticals (RXRX). Shares have added about 16.2% in that time frame, outperforming the S&P 500. But investors have to be ...

Recursion's pitch to its customers, which are major biopharma companies, is that collaborating with it will reduce research and development (R&D) costs and timelines. To accomplish that, it employs a ...

Recursion Pharmaceuticals, a drug discovery company that applies artificial intelligence to biology, is shoring up its technology platform by buying two startups that bolster its chemistry ...